Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2009 Jul 07;10627:11154-9. doi: 10.1073/pnas.0901591106.
Show Gene links
Show Anatomy links
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.
Kim MK, McGarry TJ, O Broin P, Flatow JM, Golden AA, Licht JD.
???displayArticle.abstract??? WT1, a critical regulator of kidney development, is a tumor suppressor for nephroblastoma but in some contexts functions as an oncogene. A limited number of direct transcriptional targets of WT1 have been identified to explain its complex roles in tumorigenesis and organogenesis. In this study we performed genome-wide screening for direct WT1 targets, using a combination of ChIP-ChIP and expression arrays. Promoter regions bound by WT1 were highly G-rich and resembled the sites for a number of other widely expressed transcription factors such as SP1, MAZ, and ZNF219. Genes directly regulated by WT1 were implicated in MAPK signaling, axon guidance, and Wnt pathways. Among directly bound and regulated genes by WT1, nine were identified in the Wnt signaling pathway, suggesting that WT1 modulates a subset of Wnt components and responsive genes by direct binding. To prove the biological importance of the interplay between WT1 and Wnt signaling, we showed that WT1 blocked the ability of Wnt8 to induce a secondary body axis during Xenopus embryonic development. WT1 inhibited TCF-mediated transcription activated by Wnt ligand, wild type and mutant, stabilized beta-catenin by preventing TCF4 loading onto a promoter. This was neither due to direct binding of WT1 to the TCF binding site nor to interaction between WT1 and TCF4, but by competition of WT1 and TCF4 for CBP. WT1 interference with Wnt signaling represents an important mode of its action relevant to the suppression of tumor growth and guidance of development.
Bailey,
Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
1994, Pubmed
Bailey,
Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
1994,
Pubmed Bickmore,
Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript.
1992,
Pubmed Bridgewater,
Canonical WNT/beta-catenin signaling is required for ureteric branching.
2008,
Pubmed Chang,
Wt1 negatively regulates beta-catenin signaling during testis development.
2008,
Pubmed Eisermann,
Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer.
2008,
Pubmed Englert,
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
1995,
Pubmed Englert,
Induction of p21 by the Wilms' tumor suppressor gene WT1.
1997,
Pubmed Fraizer,
Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
2004,
Pubmed Fukuzawa,
Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
2004,
Pubmed Ghosh,
Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators.
2001,
Pubmed Gross,
The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development.
2003,
Pubmed Haber,
WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.
1993,
Pubmed Hatzis,
Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells.
2008,
Pubmed He,
Identification of c-MYC as a target of the APC pathway.
1998,
Pubmed Herzer,
The Wilms tumor suppressor gene wt1 is required for development of the spleen.
,
Pubmed Ijpenberg,
Wt1 and retinoic acid signaling are essential for stellate cell development and liver morphogenesis.
2007,
Pubmed Kamei,
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.
1996,
Pubmed Kim,
A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.
2008,
Pubmed Koesters,
Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
1999,
Pubmed Lee,
Wilms tumor and the WT1 gene.
2001,
Pubmed Lee,
The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.
1999,
Pubmed Li,
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
2004,
Pubmed Luo,
The tumor suppressor gene WT1 inhibits ras-mediated transformation.
1995,
Pubmed Mahony,
STAMP: a web tool for exploring DNA-binding motif similarities.
2007,
Pubmed Mahony,
Transcription factor binding site identification using the self-organizing map.
2005,
Pubmed Maiti,
Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
2000,
Pubmed Morrison,
WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.
2008,
Pubmed Morrison,
WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
2005,
Pubmed Nusse,
Cancer. Converging on beta-catenin in Wilms tumor.
2007,
Pubmed Ogawa,
Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
1993,
Pubmed Oji,
Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma.
2003,
Pubmed Oji,
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
2003,
Pubmed Park,
Wnt/beta-catenin signaling regulates nephron induction during mouse kidney development.
2007,
Pubmed Piper,
Expression of the vertebrate Slit gene family and their putative receptors, the Robo genes, in the developing murine kidney.
2000,
Pubmed Quandt,
MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.
1995,
Pubmed Rivera,
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
2007,
Pubmed Roth,
Finding DNA regulatory motifs within unaligned noncoding sequences clustered by whole-genome mRNA quantitation.
1998,
Pubmed Sandelin,
JASPAR: an open-access database for eukaryotic transcription factor binding profiles.
2004,
Pubmed Scharnhorst,
Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties.
1999,
Pubmed Schmidt-Ott,
Dissecting stages of mesenchymal-to-epithelial conversion during kidney development.
2006,
Pubmed Sim,
Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
2002,
Pubmed Takemaru,
The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression.
2000,
Pubmed
,
Xenbase Udtha,
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
2003,
Pubmed Uschkereit,
Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation.
2007,
Pubmed Vainio,
A road to kidney tubules via the Wnt pathway.
2000,
Pubmed Wagner,
Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms' tumor suppressor Wt1.
2006,
Pubmed Wang,
A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1.
2001,
Pubmed Wingender,
TRANSFAC: an integrated system for gene expression regulation.
2000,
Pubmed Yochum,
Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells.
2007,
Pubmed Zhang,
Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin.
2003,
Pubmed
